Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Kly board and ceo decisions over past year tells it all
View:
Post by edrose on Jul 17, 2020 10:26am

Kly board and ceo decisions over past year tells it all

They pushed for talent,stero,salzman where retail investors get wiped out,kly doesn't have any money
they agreed to buy salzman without condition like getting Barda funding approved,without vote from shareholders,with conflict of interest 
kly can't even pay accountants and got haunted for not providing financials 
there's still pumping by some people

it will be easy to prove shareholder oppression
Comment by Jack4000 on Jul 17, 2020 11:05am
This post has been removed in accordance with Community Policy
Comment by Jayjayt on Jul 17, 2020 11:09am
who vote ? I dint
Comment by Jack4000 on Jul 17, 2020 11:15am
This post has been removed in accordance with Community Policy
Comment by Jayjayt on Jul 17, 2020 11:17am
i think ed is talking about kaly shareholders vote.not Salzman shareholders
Comment by Jack4000 on Jul 17, 2020 11:29am
This post has been removed in accordance with Community Policy
Comment by Jayjayt on Jul 17, 2020 11:06am
lets get a law firm.
Claritas Pharmaceuticals Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities